瑞典糖尿病再分组方案在中国成人起病糖尿病中的验证
本研究在中国新诊断的成人起病糖尿病患者中应用瑞典数据驱动的5亚组分类方案(SAID、SIDD、SIRD、MOD、MARD),采用K-means与Two-Step两种方法按6项临床参数分组,共纳入2015年4月至2017年10月的15772例患者;结果显示该方案适用于中国成人起病糖尿病,其中SIDD亚组比例较高,未来仍需进一步验证长期并发症。
要点
- 中国患者聚类为5个亚组,其中SIDD占24.8%,MARD占30.9%。
- 与瑞典人群相比,中国患者SIDD亚组比例更高。
- 中国患者较瑞典患者年龄更小、BMI更低、HbA1c更高,胰岛素使用更多而二甲双胍使用更少。
核心结论
- 瑞典糖尿病再分组方案适用于中国成人起病糖尿病,其中重度胰岛素缺乏型糖尿病(SIDD)患者比例较高。
- 未来研究仍需进一步验证长期糖尿病并发症。
研究设计与样本
- 研究为在中国开展的横断面调查,纳入2015年4月至2017年10月成人起病新诊断糖尿病患者15772例,就诊场景为门诊诊疗。
- 按6项临床参数(谷氨酸脱羧酶抗体(GADA)、起病年龄、体质指数(BMI)、糖化血红蛋白A1c(HbA1c)、稳态模型评估2的β细胞功能估计值(HOMA2-B)与胰岛素抵抗估计值(HOMA2-IR)),采用K-means与Two-Step方法将患者分为5个亚组。
主要发现
- 患者聚类为5个亚组:重度自身免疫性糖尿病(SAID)占6.2%,重度胰岛素缺乏型糖尿病(SIDD)占24.8%,重度胰岛素抵抗型糖尿病(SIRD)占16.6%,轻度肥胖相关糖尿病(MOD)占21.6%,轻度年龄相关糖尿病(MARD)占30.9%。
- 与瑞典人群相比,中国人群SIDD亚组比例更高。
- 总体上中国患者较瑞典患者年龄更小、BMI更低、HbA1c更高、HOMA2-B更低、HOMA2-IR更低,胰岛素使用更多而二甲双胍使用更少。
局限性
- 原文结论提出未来研究仍需进一步验证长期糖尿病并发症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: This study applied the Swedish novel data-driven classification in Chinese newly diagnosed diabetic patients and validated its adoptability. OBJECTIVE: This study aimed to validate the practicality of the Swedish diabetes regrouping scheme in Chinese adults with newly diagnosed diabetes. DESIGN: Patients were classified into 5 subgroups by K-means and Two-Step methods according to 6 clinical parameters. SETTING: Ambulatory care. PATIENTS: A cross-sectional survey of 15 772 patients with adult-onset newly diagnosed diabetes was conducted in China from April 2015 to October 2017. INTERVENTION: None. MAIN OUTCOME MEASURES: Six parameters including glutamate decarboxylase antibodies (GADA), age of onset, body mass index (BMI), glycated hemoglobin A1c (HbA1c), homoeostatic model assessment 2 estimates of β-cell function (HOMA2-B) and insulin resistance (HOMA2-IR) were measured to calculate the patient subgroups. RESULTS: Our patients clustered into 5 subgroups: 6.2% were in the severe autoimmune diabetes (SAID) subgroup, 24.8% were in the severe insulin-deficient diabetes (SIDD) subgroup, 16.6% were in the severe insulin-resistance diabetes (SIRD) subgroup, 21.6% were in the mild obesity-related diabetes (MOD) subgroup and 30.9% were in the mild age-related diabetes (MARD) subgroup. When compared with the Swedish population, the proportion of SIDD subgroup was higher. In general, Chinese patients had younger age, lower BMI, higher HbA1c, lower HOMA2-B and HOMA2-IR, and higher insulin use but lower metformin usage than the Swedish patients. CONCLUSION: The Swedish diabetes regrouping scheme is applicable to adult-onset diabetes in China, with a high proportion of patients with the severe insulin deficient diabetes. Further validations of long-term diabetes complications remain warranted in future studies.
引用
- Li X, Yang S, Cao C, et al. Validation of the Swedish Diabetes Re-Grouping Scheme in Adult-Onset Diabetes in China. J Clin Endocrinol Metab. 2020. PMID: 32808015. doi:10.1210/clinem/dgaa524
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。